All In Biotech

Drug Trial Radar · NCT06433219

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

An Open-label, Multicenter, Randomized Phase 2 Study of the ATR Inhibitor Tuvusertib in Combination With the PARP Inhibitor Niraparib or the ATM Inhibitor Lartesertib in Participants With BRCA Mutant and/or Homologous Recombination deficiency (HRD)-Positive Epithelial Ovarian Cancer That Progressed on Prior PARP Inhibitor Therapy (DDRiver EOC 302)

Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

63

Actual

Start

Oct 30, 2024

Primary completion

Aug 11, 2026

Study completion Aug 11, 2026

Sponsor

Sponsor type
Industry
Collaborators
Merck KGaA, Darmstadt, Germany
First posted
May 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to measure the effect and safety of treatment with tuvusertib combined with either niraparib or lartesertib in participants with epithelial ovarian cancer and to assess any differences between tuvusertib monotherapy and combination therapy. The participants will previously have progressed while treated with a poly ADP ribose polymerase (PARP) inhibitor. The primary objectives of this study are to assess the effect of the treatment in terms of overall response, i.e. whether the tumor disappears, shrinks, remains unchanged, or gets worse and safety in terms of adverse events.

Conditions

  • Ovarian Cancer

Interventions

  • Tuvusertib (M1774)Drug

    Tuvusertib will be administered orally.

  • NiraparibDrug

    Niraparib will be administered orally. If selected from Part A, Niraparib will be administered orally in combination with Tuvusertib.

  • Lartesertib (M4076)Drug

    Lartesertib will be administered orally. If selected from Part A, Lartesertib will be administered orally in combination with Tuvusertib

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A and Part B: Confirmed Objective Response (OR) According to RECIST v1.1 as Assessed by InvestigatorTime frame: Time from randomization to final assessment or until progressive disease, death, discontinuation criteria, approximately up to 3.5 years
  2. Part A and Part B: Number of Participants With Treatment-Emergent Adverse Events (TEAE), Serious TEAEs and Related TEAEsTime frame: Time from randomization to final assessment at end of safety follow-up visit, approximately up to 3.5 years

Locations

84 sites in 13 countries. Site status is shown where the registry gives one.

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • University of California San Francisco - UCSF Medical Center

    San Francisco, California

  • Centricity Research Cancer Center - DBA CRRI John B. Amos Cancer Center Research

    Columbus, Georgia

  • University of Chicago Comprehensive Cancer Center at Silver Cross - Carolyn J. Czerkies Pavilion

    Chicago, Illinois

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Icahn School of Medicine at Mount Sinai PRIME - Mount Sinai - PRIME

    New York, New York

  • Next Oncology - Virginia

    Fairfax, Virginia

  • Virginia Cancer Specialists, PC

    Fairfax, Virginia

  • Chris O'Brien Lifehouse

    Camperdown, Australia

  • St George Private Hospital

    Kogarah, Australia

  • Liverpool Hospital - PARENT

    Liverpool, Australia

  • Cliniques Universitaires Saint-Luc - STL

    Brussels, Belgium

  • UZ Leuven

    Leuven, Belgium

  • Ålborg Universitets Hospital - PARENT

    Aalborg, Denmark

  • Rigshospitalet

    Copenhagen, Denmark

  • Sjaellands Universitetshospital - other

    Odense, Denmark

  • ICO - Site Paul Papin - service d'oncologie medicale

    Angers, France

  • Centre Francois Baclesse - Service d'Oncologie Medicale

    Caen, France

  • Centre Oscar Lambret - service de cancerologie gynecologique

    Lille, France

  • Centre Leon Berard - Service d'Oncologie Medicale

    Lyon, France

  • Groupe Hospitalier Diaconesses - Hôpital De La Croix Saint Simon - service d'oncologie medicale

    Paris, France

  • Hopital Tenon - service d'oncologie medicale

    Paris, France

  • Hôpital Cochin - Hematologie et Oncologie Médicale

    Paris, France

  • Hôpital Européen Georges Pompidou - Hématologie Oncologie

    Paris, France

  • Hôpital Saint Joseph - Paris - Service d'Oncologie-Cancerologie

    Paris, France

  • Centre Hospitalier Lyon Sud - service d'oncologie medicale

    Pierre-Bénite, France

  • Centre de Radiotherapie Clinique Sainte Anne - 300207251

    Strasbourg, France

  • Institut de Cancérologie de Strasbourg Europe - ICANS - Service d'oncologie médicale

    Strasbourg, France

  • Institut Gustave Roussy - Oncologie Médicale

    Villejuif, France

  • Charité - Campus Virchow-Klinikum - Klinik fuer Gynaekologie

    Berlin, Germany

  • Universitaetsklinikum Bonn AoeR - Frauenklinik

    Bonn, Germany

  • Universitaetsklinikum Carl Gustav Carus TU Dresden - Klinik u. Poliklinik f. Frauenheilkunde

    Dresden, Germany

  • Kliniken Essen-Mitte - Gynaekologie und Gynaekologische Onkologie

    Essen, Germany

  • Universitaetsklinikum Leipzig AoeR - Klinik und Poliklinik fuer Frauenheilkunde

    Leipzig, Germany

  • Universitaetsklinikum Muenster - Parent

    Münster, Germany

  • Universitätsklinikum Münster - Gynecology

    Münster, Germany

  • Caritas-Krankenhaus St. Josef - Klinik fuer Chirurgie

    Regensburg, Germany

  • Universitaetsklinikum Tuebingen - Parent

    Tübingen, Germany

  • Rambam Medical Center

    Haifa, Israel

Showing 40 of 84 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.